(London / New York Composite Electric) British media reported that Modna, an American pharmaceutical factory that produced coronary vaccines, refused to provide the core technology of the coronary vaccine that was developed, which caused it to break the negotiations of sales in China.

Financial Times Sunday (October 2) quoted people familiar with the negotiating in the past two years that China requires Moderna to provide its messenger ribonucleic acid (mRNA) technology, but Modner has produced itRejects in business and security considerations.

Reports pointed out that Modner has always hoped to enter the Chinese market, but abandoned in Beijing because MRNA technology was approved for sales in China.

Modner did not immediately respond to the media's inquiry.However, it is reported that Modner is still eager to have the opportunity to enter the Chinese market.

Modner chief medical officer Burton stated at the Asian media at the report that he hopes to cooperate with China to provide coronary vaccines with MRNA technology.

He said: "If China thinks there is such a demand, we are of course very eager to cooperate. There is no progress yet, but we are holding a very open attitude."

China currently does not approve the use of any foreign coronary vaccine, but relies on several types of vaccines developed in China, most of which are mainly activated vaccine technology.

Several Chinese pharmaceutical companies are competing for the development of coronary vaccines with self -made and using MRNA technology. However, the progress of new mutant strains with stronger infectious power has caused progress.

Compared with the surplus vaccine technology, MRNA vaccine technology adopted by Modner and Biontech / Pfizer can provide more lasting and better protection.

It is reported that China has provided two ways for foreign crown disease vaccine manufacturers in China: through the approval of the regulatory authorities, comprehensive technical transfer to domestic pharmaceutical companies, or maintaining technical control, but must be related to local partners, but must be related to local partners.Set up factories in China.

Modner allegedly forced to choose the first way.However, Modner has always strongly protected the company's intellectual property rights, claiming that handling technical patents cannot truly solve the supply problem.

Nevertheless, the report said that Modner has recently re -negotiated with China.

According to industry insiders, the reason why Modner was willing to restart negotiations with China was because Modner first aimed at a wealthy country market, showing weak signs of demand for crown diseases.